0 0 Meta Healthcare Ltd 11337568 false 2024-09-01 2025-08-31 2025-08-31 The principal activity of the company is the provision of other human health services. Digita Accounts Production Advanced 6.30.9574.0 true true 11337568 2024-09-01 2025-08-31 11337568 2025-08-31 11337568 bus:OrdinaryShareClass1 2025-08-31 11337568 bus:OrdinaryShareClass2 2025-08-31 11337568 bus:OrdinaryShareClass3 2025-08-31 11337568 bus:OrdinaryShareClass4 2025-08-31 11337568 core:CapitalRedemptionReserve 2025-08-31 11337568 core:RetainedEarningsAccumulatedLosses 2025-08-31 11337568 core:ShareCapital 2025-08-31 11337568 core:SharePremiumOrdinaryShares 2025-08-31 11337568 core:CurrentFinancialInstruments 2025-08-31 11337568 core:CurrentFinancialInstruments core:WithinOneYear 2025-08-31 11337568 core:FurnitureFittingsToolsEquipment 2025-08-31 11337568 bus:SmallEntities 2024-09-01 2025-08-31 11337568 bus:AuditExemptWithAccountantsReport 2024-09-01 2025-08-31 11337568 bus:FilletedAccounts 2024-09-01 2025-08-31 11337568 bus:SmallCompaniesRegimeForAccounts 2024-09-01 2025-08-31 11337568 bus:RegisteredOffice 2024-09-01 2025-08-31 11337568 bus:Director2 2024-09-01 2025-08-31 11337568 bus:Director3 2024-09-01 2025-08-31 11337568 bus:Director4 2024-09-01 2025-08-31 11337568 bus:OrdinaryShareClass1 2024-09-01 2025-08-31 11337568 bus:OrdinaryShareClass2 2024-09-01 2025-08-31 11337568 bus:OrdinaryShareClass3 2024-09-01 2025-08-31 11337568 bus:OrdinaryShareClass4 2024-09-01 2025-08-31 11337568 bus:PrivateLimitedCompanyLtd 2024-09-01 2025-08-31 11337568 bus:Agent1 2024-09-01 2025-08-31 11337568 core:OfficeEquipment 2024-09-01 2025-08-31 11337568 core:KeyManagementPersonnelCloseFamilyMembersEntitiesUnderKeyManagementPersonnelsControl 2024-09-01 2025-08-31 11337568 core:OtherRelatedPartyRelationshipType1ComponentTotalRelatedParties 2024-09-01 2025-08-31 11337568 core:OtherRelatedPartyRelationshipType2ComponentTotalRelatedParties 2024-09-01 2025-08-31 11337568 countries:EnglandWales 2024-09-01 2025-08-31 11337568 2024-08-31 11337568 core:FurnitureFittingsToolsEquipment 2024-08-31 11337568 2023-09-01 2024-08-31 11337568 2024-08-31 11337568 bus:OrdinaryShareClass1 2024-08-31 11337568 bus:OrdinaryShareClass2 2024-08-31 11337568 bus:OrdinaryShareClass3 2024-08-31 11337568 bus:OrdinaryShareClass4 2024-08-31 11337568 core:CurrentFinancialInstruments core:WithinOneYear 2024-08-31 xbrli:pure iso4217:GBP xbrli:shares

Registration number: 11337568

Prepared for the registrar
Meta Healthcare Ltd
Annual Report and Unaudited Financial Statements
for the Year Ended 31 August 2025

Meta Healthcare Ltd

Contents

Company Information | 1
Balance Sheet | 2
Notes to the Unaudited Financial Statements | 3 to 7

Meta Healthcare Ltd

Company Information

Directors | C Wagstaff S Tickle R C Patel

Registered office | Staverton Court Staverton Cheltenham Gloucestershire GL510UX

Accountants | Hazlewoods LLP Staverton Court Staverton Cheltenham GL51 0UX

Meta Healthcare Ltd

(Registration number: 11337568)
Balance Sheet as at 31 August 2025

| Note | 2025 £ | 2024 £
Current assets |  |  |
Stocks |  | 14,718 | 1,909
Debtors | 5 | 48,886 | 79,121
Cash at bank and in hand |  | 182,420 | 64,450
|  | 246,024 | 145,480
Creditors: Amounts falling due within one year | 6 | (806,023) | (696,966)
Net liabilities |  | (559,999) | (551,486)
Capital and reserves |  |  |
Called up share capital | 7 | 360 | 360
Share premium reserve |  | 811 | 811
Capital redemption reserve |  | (81) | (81)
Retained earnings |  | (561,089) | (552,576)
Shareholders' deficit |  | (559,999) | (551,486)

For the financial year ending 31 August 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

• | The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and
• | The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the directors have not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the Board on 1 April 2026 and signed on its behalf by:

C Wagstaff
Director

Meta Healthcare Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 August 2025

| 1 | General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
Staverton Court
Staverton
Cheltenham
Gloucestershire
GL510UX
England

| 2 | Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A
- 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006.

Basis of preparation

These financial statements have been prepared using the historical cost convention except for, where disclosed in these accounting policies, certain items that are shown at fair value.

The presentational currency of the financial statements is Pounds Sterling, being the functional currency of the primary economic environment in which the company operates. Monetary amounts in these financial statements are rounded to the nearest Pound.

Going concern

After reviewing the company's current forecasts and projections, together with the facilities available to the company, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. The company is reliant on the continued support from CW Pharma Limited by way of a loan of £626,047, and a loan from Tord Consulting Ltd of £121,578. The company therefore continues to adopt the going concern basis in preparing its financial statements.

Critical accounting judgements and key sources of estimation uncertainty
In the application of the company’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.
The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.

Judgements

No significant judgements have been made by management in preparing these financial statements.

Meta Healthcare Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 August 2025

Key sources of estimation uncertainty

No key sources of estimation uncertainty have been identified by management in preparing these financial statements other than those detailed in these accounting policies.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts and after eliminating sales within the company.
The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Tax

The tax expense for the period comprises current and deferred tax. Tax is recognised in the profit and loss account, except that a charge attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Tangible assets

Tangible assets are stated in the statement of financial position at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.
The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class | Depreciation method and rate
Computer equipment | 33% straight line

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.
Trade debtors are recognised initially at the transaction price. All trade debtors are repayable within one year and hence are included at the undiscounted cost of cash expected to be received. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the debtors.

Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost is determined using the first-in, first-out (FIFO) method.
The cost of finished goods and work in progress comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the inventories to their present location and condition. At each reporting date, stocks are assessed for impairment. If stocks are impaired, the carrying amount is reduced to its selling price less costs to complete and sell; the impairment loss is recognised immediately in profit or loss.

Meta Healthcare Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 August 2025

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.
Trade creditors are recognised initially at the transaction price and all are repayable within one year and hence are included at the undiscounted amount of cash expected to be paid.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Financial instruments

Classification
Financial instruments are classified and accounted for according to the substance of the contractual arrangement, as financial assets, financial liabilities or equity instruments. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities. Where shares are issued, any component that creates a financial liability of the company is presented as a liability on the balance sheet. The corresponding dividends relating to the liability component are charged as interest expenses in the profit and loss account.

Recognition and measurement
All financial assets and liabilities are initially measured at transaction price (including transaction costs), except for those financial assets classified as at fair value through profit or loss, which are initially measured at fair value (which is normally the transaction price excluding transaction costs), unless the arrangement constitutes a financing transaction. If an arrangement constitutes a financing transaction, the financial asset or financial liability is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Impairment
Assets, other than those measured at fair value, are assessed for indicators of impairment at each balance sheet date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss as described below.
A non financial asset is impaired where there is objective evidence that, as a result of one or more events that occurred after initial recognition, the estimated recoverable value of the asset has been reduced. The recoverable amount of an asset is the higher of its fair value less costs to sell and its value in use.

| 3 | Staff numbers

The average number of persons employed by the company during the year, was nil (2024 - nil).

Meta Healthcare Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 August 2025

| 4 | Tangible assets

| Office equipment £ | Total £
Cost
At 1 September 2024 | 833 | 833
At 31 August 2025 | 833 | 833
Depreciation
At 1 September 2024 | 833 | 833
At 31 August 2025 | 833 | 833
Carrying amount
At 31 August 2025 | - | -

| 5 | Debtors

| Note | 2025 £ | 2024 £
Trade debtors |  | 20,198 | 50,775
Receivables from related parties | 8 | 1,057 | 1,057
Prepayments |  | 4,105 | 7,312
Other debtors |  | 23,526 | 19,977
|  | 48,886 | 79,121

| 6 | Creditors

| Note | 2025 £ | 2024 £
Due within one year |  |  |
Trade creditors |  | 41,972 | 34,062
Amounts due to related parties | 8 | 746,545 | 648,276
Taxation and social security |  | 15,831 | 6,533
Accruals and deferred income |  | 1,675 | 8,095
|  | 806,023 | 696,966

| 7 | Share capital

Allotted, called up and fully paid shares

| 2025 | 2024
| No. | £ | No. | £
Ordinary A shares of £1 each | 81 | 81 | 81 | 81
Ordinary B shares of £1 each | 162 | 162 | 162 | 162
Ordinary C shares of £1 each | 81 | 81 | 81 | 81
Ordinary D shares of £1 each | 36 | 36 | 36 | 36
| 360 | 360 | 360 | 360

The different classes of share referred to above carry separate rights to dividends but, in all other significant respects, rank pari passu.

Meta Healthcare Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 August 2025

| 8 | Related party transactions

Summary of transactions with key management

Key management personnel are considered to be the directors of the company.
R Patel
(R Patel is a current shareholder and director of Meta Healthcare Ltd)
As at 31 August 2025, the company was owed £81 (2024 - £81) from R Patel. There are no fixed repayment terms and no interest is charged on the outstanding amount.
S Tickle
(S Tickle is a current shareholder and director of Meta Healthcare Ltd)
As at 31 August 2025, the company was owed £126 (2024 - £126) from S Tickle. There are no fixed repayment terms and no interest is charged on the outstanding amount.

Summary of transactions with other related parties

Firstline Pharma Ltd (Ravalco Ltd is a shareholder of Firstline Pharma Ltd) As at 31 August 2025, the amount owed by Meta Healthcare Ltd to Firstline Pharma Ltd was £nil (2024 - £11,035). Interest of £nil (2024 - £4,624) is charged on the outstanding amount. This loan was fully repaid in the prior year.
A L Comparat (Ms Comparat is the spouse of C Wagstaff, a director in Meta Healthcare Ltd in the year ended 31 August 2025) As at 31 August 2025, the company owed £10,800 (2024 - £10,800) to A L Comparat. There are no fixed repayment terms and no interest is charged on the outstanding amount.
Tord Consulting Ltd (R Patel is a director of Tord Consulting and of Meta Healthcare) As at 31 August 2025, the company owed £109,698 (2024 - £89,992) toTord Consulting Ltd. There are no fixed repayment terms and interest of £9,706(2024 - £6,291) is charged on the outstanding amount.
Hualel Holdings Ltd (C Wagstaff is a director of Hualel Holdings Ltd and a former director of Meta Healthcare) As at 31 August 2025, the company was owed £850 (2024 - £850) from Hualel Holdings Ltd. There are no fixed repayment terms and no interest is charged on the outstanding amount.
CW Pharma Consultants Ltd (C Wagstaff is a director of HCW Pharma Consultants Ltd and a former director of Meta Healthcare) As at 31 August 2025, the company owed £626,047 (2024 - £536,449) to CW Pharma Consultants Ltd. There are no fixed repayment terms and interest of £54,598 (2024 - £44,866) is charged on the outstanding amount.